Fibrosis Risk Assessment – ICST

Fibrosis Risk Assessment

The severity of abnormality of liver blood tests does not always correlate with the severity of underlying liver blood tests, and therefore a Fibrosis Risk Assessment is used to quantify the risk of fibrosis.

There are a number of FRA tools that can be used, including:

  • NAFLD (specific to fatty liver disease only)
  • Fib-4
  • AST:ALT ratio (ratio greater than 1 identifying a high risk of liver fibrosis)

 

For the purposes of the All-Wales Liver Blood Tests pathway, an automatic AST:ALT ratio is being adopted as a reflex FRA when a patient is sent for an additional liver blood test.

If a patient has a score that categorises them as high risk of liver fibrosis, this does not confirm the diagnosis of liver fibrosis and the patient should be referred to a Hepatology Outpatient clinic for additional testing.

Fibrosis Risk Assessment

The severity of abnormality of liver blood tests does not always correlate with the severity of underlying liver blood tests, and therefore a Fibrosis Risk Assessment is used to quantify the risk of fibrosis.

There are a number of FRA tools that can be used, including:

  • NAFLD (specific to fatty liver disease only)
  • Fib-4
  • AST:ALT ratio (ratio greater than 1 identifying a high risk of liver fibrosis)

 

For the purposes of the All-Wales Liver Blood Tests pathway, an automatic AST:ALT ratio is being adopted as a reflex FRA when a patient is sent for an additional liver blood test.

If a patient has a score that categorises them as high risk of liver fibrosis, this does not confirm the diagnosis of liver fibrosis and the patient should be referred to a Hepatology Outpatient clinic for additional testing.

Mark as Understood

© Institute of Clinical Science and Technology (ICST) 2020

Support: admin@clinicalscience.org.uk